CN1970001B - Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis - Google Patents
Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis Download PDFInfo
- Publication number
- CN1970001B CN1970001B CN2005101045532A CN200510104553A CN1970001B CN 1970001 B CN1970001 B CN 1970001B CN 2005101045532 A CN2005101045532 A CN 2005101045532A CN 200510104553 A CN200510104553 A CN 200510104553A CN 1970001 B CN1970001 B CN 1970001B
- Authority
- CN
- China
- Prior art keywords
- fructus schisandrae
- schisandrae chinensis
- injection
- kwr
- kurarinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 165
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 165
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 164
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 164
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 208000006454 hepatitis Diseases 0.000 title claims description 15
- 231100000283 hepatitis Toxicity 0.000 title claims description 13
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 title claims description 13
- 240000006079 Schisandra chinensis Species 0.000 title abstract description 10
- 235000008422 Schisandra chinensis Nutrition 0.000 title abstract description 9
- 235000013399 edible fruits Nutrition 0.000 title abstract description 5
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 title description 78
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 title description 65
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 title description 65
- 150000004676 glycans Chemical class 0.000 claims abstract description 58
- 235000017709 saponins Nutrition 0.000 claims abstract description 57
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 56
- 239000005017 polysaccharide Substances 0.000 claims abstract description 56
- 150000007949 saponins Chemical class 0.000 claims abstract description 56
- 229930182490 saponin Natural products 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims description 100
- 238000002347 injection Methods 0.000 claims description 51
- 239000007924 injection Substances 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 25
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 12
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 9
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 229930182494 ginsenoside Natural products 0.000 claims description 7
- 229940089161 ginsenoside Drugs 0.000 claims description 7
- 239000012259 ether extract Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 61
- 239000000284 extract Substances 0.000 abstract description 25
- 208000002672 hepatitis B Diseases 0.000 abstract description 3
- 208000005176 Hepatitis C Diseases 0.000 abstract description 2
- 208000005252 hepatitis A Diseases 0.000 abstract description 2
- 241000219784 Sophora Species 0.000 abstract 3
- 239000000470 constituent Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 117
- 239000000243 solution Substances 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 85
- 239000008215 water for injection Substances 0.000 description 34
- 229960004756 ethanol Drugs 0.000 description 32
- 238000000034 method Methods 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- 239000000706 filtrate Substances 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000005516 engineering process Methods 0.000 description 24
- 239000007788 liquid Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 229920001214 Polysorbate 60 Polymers 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 238000004321 preservation Methods 0.000 description 18
- 239000013558 reference substance Substances 0.000 description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 238000007689 inspection Methods 0.000 description 16
- 239000008187 granular material Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 238000012856 packing Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 239000011265 semifinished product Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002131 composite material Substances 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 235000020710 ginseng extract Nutrition 0.000 description 11
- 238000004064 recycling Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 238000001291 vacuum drying Methods 0.000 description 11
- 210000003462 vein Anatomy 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 235000001727 glucose Nutrition 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000005262 decarbonization Methods 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000009287 sand filtration Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 239000013505 freshwater Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 4
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 4
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229930014456 matrine Natural products 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- -1 reflux Substances 0.000 description 4
- 239000008227 sterile water for injection Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 3
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- RSJOBNMOMQFPKQ-ZVGUSBNCSA-L copper;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O RSJOBNMOMQFPKQ-ZVGUSBNCSA-L 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- LMYVDPWHMJXPIY-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanol Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCO LMYVDPWHMJXPIY-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- YEZWWUMWIFKEQM-UHFFFAOYSA-N O.OC.ClC(Cl)Cl.CCOC(C)=O Chemical compound O.OC.ClC(Cl)Cl.CCOC(C)=O YEZWWUMWIFKEQM-UHFFFAOYSA-N 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940086234 acetaminophen 300 mg Drugs 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- QMGGMESMCJCABO-UHFFFAOYSA-N n-oxysophocarpine Chemical compound C12C3CCC[N+]2([O-])CCCC1CN1C3CC=CC1=O QMGGMESMCJCABO-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a pharmaceutical composition and its preparation, wherein the constituents include (by weight ratio) flavescent sophora root extract 50-2000 parts, schisandra fruit 500-20000 parts, ginseng 500-20000 parts, or flavescent sophora root extract 50-2000 parts, schisandra fruit extract 15-600 parts, ginseng polysaccharides 6-240 parts, or flavescent sophora root extract 50-2000 parts, schisandra fruit extract 15-600 parts, ginseng saponins 6-240 parts. The pharmaceutical composition can be prepared into any clinically or pharmaceutically acceptable dose forms, and can be used for treating hepatitis A, hepatitis B and hepatitis C.
Description
1, technical field
The present invention relates to a kind of pharmaceutical composition that is used for the treatment of hepatitis class disease of making by kurarinone, Fructus Schisandrae Chinensis or its extract and Radix Ginseng or its extract and preparation method thereof, belong to medical technical field.
2, background technology
China is the district occurred frequently of viral hepatitis, has the crowd of 8%-10% to be hepatitis B virus carriers approximately, is about 1.3 hundred million people, account for 1/3 of global hepatitis B virus carriers, wherein have 3,000 ten thousand people to suffer from chronic hepatitis approximately, it is about about 1,400,000 that average year is sent out case load, annual because of hepatitis about 300,000 people that die that die of illness.Hepatitis C virus carrier 0.38 hundred million people adds the hepatitis of other types, suffers from nearly 200,000,000 people of total number of persons of hepatitis, estimate every year due to illness virus hepatitis cause direct economic loss 30,000,000,000～50,000,000,000 RMB.Therefore, the medicine of hepatitis is treated in research and development safely and effectively, becomes the problem that presses for solution.
Kurarinone is the alkaloid that extracts from leguminous plant Herba Sophorae alopecuroidis, Radix Sophorae Flavescentis, and Main Ingredients and Appearance is the N-oxysophocarpine of oxymatrine and minute quantity.Kurarinone has good antihepatitic activity: use the clinical symptoms of Oxymatrine in Treating Chronic Hepatitis B, as weak, poor appetite and abdominal distention etc., effective percentage is about 90%.Liver, splenomegaly have retraction in various degree, and periphery leukopenia and thrombocytopenia are had certain rising effect.Particularly aspect the improving of liver function effect, obtain good efficacy.
Kurarinone
Fructus Schisandrae Chinensis be magnoliaceae schisandra Schisandra chinensis (Turcz.) Baill. and schisandra chinensis Schisandrasphenanthera Rehd.et Wils. dry mature fruit.Sour in the mouth, sweet, warm in nature, return lung, the heart, kidney channel, have the convergence astringent or styptic treatment for spontaneous sweating, supplementing QI for promoting the production of body fluid, the effect of kidney calming.Modern study shows that Fructus Schisandrae Chinensis has following pharmacological action: 1. can strengthen cerebral cortex excitement and process of inhibition, make its mutual balance.2. obvious sedation, with synergism such as pentobarbital sodium, chlorpromazine, the convulsions that the antagonism beta stimulant causes has the characteristics of tranquilizer.3. regulate immunity, stablize the liver cell film, protect organelle, nucleus, promote pathological repair, improve liver function.
Radix Ginseng is the dry root and rhizome of Araliaceae Radix Ginseng Panax ginseng C.A.Mey..Sweet in the mouth, little hardship, property is flat; Return spleen, lung, heart channel; Have strongly invigorating primordial QI, multiple arteries and veins takes off admittedly, and invigorating the spleen to benefit the lung promotes the production of body fluid, the effect of calming the nerves.Modern study shows that Radix Ginseng has following pharmacological action: 1. Radix Ginseng can stimulating central nervous system system, accelerate the conduction of neural impulse, strengthen trained reflex, improve analytic function.2. can excited hypophysis-interrenal system, the adrenal cortex reinforcing function improves the body resistance that stimulates of bad condition to external world.3. strong effect is arranged, body is strengthened disease resistance, raising work is renderd a service, and reduces fatigue, and weight increase improves sleep etc.4. this product can make cardiac contractile force strengthen in a small amount in right amount, and palpitating speed has the effect of similar cardiotonic glycoside.5. Radix Ginseng also has the effect of promoting sexual gland hormone sample, can promote men and women's gonad function.6. blood sugar lowering, and have synergism with islets of langerhans.7. improve digestive and absorptive functions, appetite stimulator promotes proteinic synthetic.8. also influential to metabolism, hyperglycemia there is inhibitory action, again can the cholesterol regulating metabolism, suppress the generation of hypercholesterolemia.9. Radix Ginseng can also diuresis, and its effect is similar to desoxycortone, may be because the aldosterone secretion is increased, thereby promotes sodium retention and make the minimizing of urinating.
At present, utilize the interaction of kurarinone, Fructus Schisandrae Chinensis and Radix Ginseng, composition of prescription is used to prepare the medicine for the treatment of the hepatitis aspect, does not appear in the newspapers as yet.
3, summary of the invention
In order to meet clinical needs, better treat diseases such as hepatitis, improve the people ' s health level, the invention provides a kind of new pharmaceutical composition and preparation method thereof.
Pharmaceutical composition of the present invention is mainly made by following bulk drugs: 50～2000 parts of kurarinones, 500～20000 parts of Fructus Schisandrae Chinensis, 500～20000 parts of Radix Ginsengs, be preferably: 100～800 parts of kurarinones, 1000～10000 parts of Fructus Schisandrae Chinensis, 1000～10000 parts of Radix Ginsengs, the best is: 400 parts of kurarinones, 3000 parts of Fructus Schisandrae Chinensis, 4000 parts of Radix Ginsengs.
Fructus Schisandrae Chinensis in the crude drug of aforementioned pharmaceutical compositions, Radix Ginseng can prepare extract with The suitable solvent and method, total extract is made arbitrary preparation with other crude drug and mixing acceptable accessories again, and main effective ingredient contained in the total extract is: Fructus Schisandrae Chinensis lignin (as schisandrin), ginseng polysaccharide or Radix Ginseng total saponins.
Fructus Schisandrae Chinensis mentioned above can obtain Fructus Schisandrae Chinensis extrat through extracting processing with The suitable solvent, wherein solvent preferred water or alcohol, and the extracting method of Fructus Schisandrae Chinensis can be infusion process, percolation, decocting method, supercritical CO
2Extraction, reflux extraction or continuous extraction.As preparing Fructus Schisandrae Chinensis extrat by water extract-alcohol precipitation, ethanol percolation, alcohol extraction upper prop.
The invention provides a kind of preferred extraction process of Fructus Schisandrae Chinensis extrat, detailed process is as follows:
Get schisandra chinensis medicinal material, be ground into coarse powder, decoct with water secondary, per 2 hours, filter, filtrate is concentrated into the concentrated solution of relative density 1.10～1.15, add ethanol and make and contain alcohol amount and reach 60%, cold preservation was placed 24 hours, filtered, filtrate recycling ethanol also is concentrated into the concentrated solution of relative density 1.10～1.15, adds ethanol again and makes and contain the alcohol amount and reach 80%, and cold preservation was placed 24 hours, filter, filtrate recycling ethanol also is concentrated into the thick paste of relative density 1.30～1.35, vacuum drying, promptly.
By the Fructus Schisandrae Chinensis extrat of this prepared, yield is 2～4%, and schisandrin content is not less than 10%, and ether-soluble extractives content is not less than 30%.
Fructus Schisandrae Chinensis also can be by following prepared, but is not limited only to following method:
Method 1: get schisandra chinensis medicinal material, be ground into coarse powder, add 60% ethanol and decoct secondary, per 2 hours, filter, filtrate recycling ethanol also is concentrated into the concentrated solution of relative density 1.10～1.15, adds ethanol again and makes and contain the alcohol amount and reach 80%, and cold preservation was placed 24 hours, filter, filtrate recycling ethanol also is concentrated into the thick paste of relative density 1.30～1.35, vacuum drying, promptly.By the Fructus Schisandrae Chinensis extrat of this prepared, yield is 1～5%, and schisandrin content is not less than 6%, and ether-soluble extractives content is not less than 20%.
Method 2: get schisandra chinensis medicinal material, be ground into coarse powder, decoct with water secondary, per 2 hours, filter, filtrate is concentrated into the concentrated solution of relative density 1.10～1.15, add ethanol and make and contain alcohol amount and reach 70%, cold preservation was placed 24 hours, filtered, filtrate recycling ethanol also is concentrated into the concentrated solution of relative density 1.10～1.15, adds ethanol again and makes and contain the alcohol amount and reach 90%, and cold preservation was placed 24 hours, filter, filtrate recycling ethanol also is concentrated into the thick paste of relative density 1.30～1.35, vacuum drying, promptly.By the Fructus Schisandrae Chinensis extrat of this prepared, yield is 1.5～5.5%, and schisandrin content is not less than 8%, and ether-soluble extractives content is not less than 25%.
Radix Ginseng mentioned above can obtain Radix Ginseng extract through extracting processing with The suitable solvent, extract solvent preferred water or ethanol, extracting method can be infusion process, percolation, decocting method, reflux extraction or continuous extraction, the effective ingredient of extract is ginseng polysaccharide or Radix Ginseng total saponins, and content of effective preferably is not less than 50%.
But also reference literature method preparation of the extracting method of Radix Ginseng: can be as the ginseng polysaccharide according to Chinese patent application CN200410000209.4 preparation, Radix Ginseng total saponins can prepare according to Chinese patent application CN00110418.7.
The invention provides the preferred extraction process of Radix Ginseng, detailed process is as follows:
With polysaccharide be main effective ingredient Radix Ginseng extract (hereinafter to be referred as: the preferred for preparation technology ginseng polysaccharide) is as follows:
Get the ginseng crude drug, chopping is used 75% ethanol, reflux, extract, 4 hours, filter, medicinal residues dry, and decoct with water five times, merge decoction liquor, add 0.3% active carbon, stirred 30 minutes, standing over night filters, filtrate is crossed resin column, collects effluent, and concentrating under reduced pressure adds ethanol and makes and contain the alcohol amount and reach 95%, cold preservation filters, and gets precipitation and uses washing with acetone, drains acetone, taking-up is deposited in 60～80 ℃ of dryings, pulverizes, and gets powder promptly.
By the Radix Ginseng extract of this prepared, yield is 0.5～2%, and ginseng polysaccharide's content is not less than 50%.
The ginseng polysaccharide also can be by following prepared, but is not limited only to following method:
Method 1: get Radix Ginseng, chopping adds the water reflux, extract, three times, each 2 hours, add 10 times of amounts of water for the first time, two, three times is 8,8 times of amounts, collecting decoction, filter, it is 1.16～1.24 that filtrate decompression is concentrated into relative density, crosses macroporous resin column, collect effluent, be evaporated to the thick paste shape, vacuum drying, promptly.By the Radix Ginseng extract of this prepared, yield is 4～6%, and ginseng polysaccharide's content is not less than 40%.
Method 2: get Radix Ginseng, 80% ethanol is used in chopping, reflux, extract, 3 hours filters, and medicinal residues dry, decoct with water three times, each 1.5 hours, add 10 times of amounts of water, merge decoction liquor, filter, it is 1.15～1.20 that filtrate decompression is concentrated into relative density, crosses macroporous resin, effluent is evaporated to the thick paste shape, and spray drying promptly.By the Radix Ginseng extract of this prepared, yield is 2～4%, and ginseng polysaccharide's content is not less than 45%.
The invention provides with total saponins be main effective ingredient Radix Ginseng extract (hereinafter to be referred as Radix Ginseng total saponins) preferred for preparation technology, specific as follows:
Get the ginseng crude drug, be ground into particulate, add 10 times of amount alcohol reflux secondaries, each 3 hours, merge extractive liquid,, cold preservation filters, and filtrate recycling ethanol also is concentrated into thick paste, add water to an amount of (making every 1ml be equivalent to crude drug 1g), stir evenly, cold preservation filters, filtrate is added on the macroporous resin column of having handled well, water with 2V～3V column volume carries out eluting earlier, discards water lotion, 80% ethanol elution of 3 times of column volumes of reuse, collect eluent, reclaim ethanol and be evaporated to the thick paste of relative density 1.30～1.35, vacuum drying, promptly.
By the Radix Ginseng total saponins extract that this prepared obtains, yield is 1～2%, and Radix Ginseng total saponins content is not less than 50%, ginsenoside Re, ginsenoside Rg
1Content is not less than 30%.
Radix Ginseng total saponins also can be by following prepared, but is not limited only to following method:
Method 1: get the ginseng crude drug, be ground into particulate, add the alcohol reflux secondary, each 4 hours, add 10 times of amounts of alcohol, merge extractive liquid, at every turn, cold preservation, filter, filtrate recycling ethanol also is concentrated into thick paste, and thin up to relative density is 1.15～1.20, add 1/2 times of saturated n-butanol extraction of water gaging 3 times, merge n-butyl alcohol liquid, the reclaim under reduced pressure n-butyl alcohol is to the thick paste shape, and spray drying promptly.By the Radix Ginseng extract of this prepared, yield is 4～5%, and Radix Ginseng total saponins content is not less than 35%, ginsenoside Re, ginsenoside Rg
1Content and be not less than 20%.
Method 2: get the ginseng crude drug, be ground into particulate, add alcohol reflux three times, add for the first time 10 times of amounts of alcohol, two, three times is 8,8 times of amounts, each 2 hours, merge extractive liquid, filters, and reclaims ethanol and is concentrated into thick paste, add water in right amount, stir evenly cold preservation, filter, filtrate adds 3 concentrating under reduced pressure of 1/2 times of saturated n-butanol extraction of water gaging, merges n-butyl alcohol liquid, the reclaim under reduced pressure n-butyl alcohol is to the thick paste shape, and spray drying promptly.By the Radix Ginseng extract of this prepared, yield is 3～5%, and Radix Ginseng total saponins content is for being not less than 40%, ginsenoside Re, ginsenoside Rg
1Content and be no less than 20%.
Pharmaceutical composition of the present invention can also be made by kurarinone, Fructus Schisandrae Chinensis extrat, ginseng polysaccharide or Radix Ginseng total saponins.Calculate with respect to the yield of medical material according to extract, compound medicine of the present invention can have following two kinds of different proportionings, is respectively by ratio of weight and the number of copies:
Proportioning 1: 50～2000 parts of kurarinones, 15～600 parts of Fructus Schisandrae Chinensis extrats, 6～240 parts of ginseng polysaccharides; Be preferably: 100～800 parts of kurarinones, 30～300 parts of Fructus Schisandrae Chinensis extrats, 12～120 parts of ginseng polysaccharides; Optimum is: 400 parts of kurarinone extracts, 60～120 parts of Fructus Schisandrae Chinensis extrats, 20～80 parts of ginseng polysaccharides.
Proportioning 2: 50～2000 parts of kurarinones, 15～600 parts of Fructus Schisandrae Chinensis extrats, 6～240 parts of Radix Ginseng total saponinss; Be preferably: 100～800 parts of kurarinones, 30～300 parts of Fructus Schisandrae Chinensis extrats, 12～120 parts of Radix Ginseng total saponinss; Optimum is: 400 parts of kurarinone extracts, 60～120 parts of Fructus Schisandrae Chinensis extrats, 20～80 parts of Radix Ginseng total saponinss.
In the said ratio, schisandrin content preferably is not less than 5% in the Fructus Schisandrae Chinensis extrat, and the ether extract content preferably is not less than 15%; Ginseng polysaccharide's content preferably is not less than 30%, and Radix Ginseng total saponins content preferably is not less than 30%, and ginsenoside Re wherein and ginsenoside Rg1's content preferably are not less than 15%.
More than form to be by weight as proportioning, when producing, can or reduce according to the corresponding proportion increase, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the gram also, weight can increase or reduce, but the constant rate of weight proportion between each composition.
More than form,, can make the preparation of 100～10000 consumptions,, can be made into 100～10000,1～10 of each consumption as injection as if being unit with the gram.As tablet, can be made into 100～10000, take 1～10 at every turn.
The ratio of above weight proportion obtains through science screening, and for especial patient, the ratio of can corresponding adjustment forming increases or reduce being no more than 100%.The consumption of drug component of the present invention is groped to sum up to draw through the inventor in a large number, and each amounts of components all has better curative effect in above-mentioned weight portion scope.
The invention provides a kind of medicine that is used to prepare treatment hepatitis class disease, can be used for various types of hepatitis such as hepatitis A, hepatitis B, hepatitis C.
Pharmaceutical composition of the present invention can add one or more pharmaceutically acceptable carriers, with oral, snuffing is gone into or the mode of parenteral is applied to the patient who needs this treatment.Be used for when oral, can be made into conventional solid preparation, as tablet, capsule, soft capsule, dispersible tablet, oral liquid, granule, chewable tablet, oral cavity disintegration tablet, drop pill, slow releasing tablet, slow releasing capsule, controlled release tablet, controlled release capsule, make liquid preparation such as water or oil-suspending agent or other liquid preparation such as syrup etc.; When being used for parenteral, can be made into solution, water or the oil-suspending agent etc. of injection, as liquid drugs injection, freeze-dried powder, aseptic powder injection, transfusion etc.The preferred dosage form of this compositions is injection or oral formulations.
Pharmaceutical composition of the present invention can adopt the conventional method production in the existing pharmaceutical field, can add various pharmaceutically acceptable carriers when needing.Described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant of pharmaceutical field routine etc.
Pharmaceutical composition of the present invention in order to increase its dissolubility, can add solubilizing agents such as Tween-80 when making injection.Can add the isoosmotic adjusting agent that is used to regulate osmotic pressure in the transfusion, for example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium lactate, glucose, xylitol, sorbitol and dextran etc., preferred sodium chloride or glucose.Can add excipient in the powder pin, for example, mannitol, glucose etc.
Pharmaceutical composition of the present invention has the following advantages:
(1) the invention provides a kind of new pharmaceutical composition that is used for the treatment of hepatitis, satisfied clinical needs.
(2) studies have shown that by pharmacodynamic experiment first: the chmice acute hepatic injury due to pharmaceutical composition Abensanil of the present invention, the carbon tetrachloride has protective effect, can suppress the breeding of dhbv dna, the rat liver fibrosis due to can anti-carbon tetrachloride.Three medical instruments have synergistic function, and are evident in efficacy.This is that those of ordinary skills are unexpected.
(3) each proportioning of the present composition is carried out pharmacodynamic study, drawn the optimal proportion of the present composition.
(4) the present invention can directly feed intake with raw material or extract, and preparation technology is simple, can make between the different batches medicine mass discrepancy little, and drug quality is more uniform and stable.
(5) confirm drug combination injection safety and stability of the present invention by specific safety test and stability experiment.
(6) kurarinone has good antihepatitic activity, and Fructus Schisandrae Chinensis and Radix Ginseng are done to assist and can be significantly improved anti-hepatitis curative effect, the drug combination determined curative effect, and reduced relative dosage, be with a wide range of applications.
Below example is further set forth the beneficial effect of medicine of the present invention by experiment, and these experimental examples comprise the pharmacodynamic experiment of pharmaceutical composition of the present invention, kurarinone, Fructus Schisandrae Chinensis extrat and ginseng polysaccharide's compositions hereinafter to be referred as
The KWR composition I, the compositions of kurarinone, Fructus Schisandrae Chinensis extrat and Radix Ginseng total saponins hereinafter to be referred as
KWR composition I IUsed Fructus Schisandrae Chinensis extrat is taken from embodiment 1 in the experimental example, and the ginseng polysaccharide gets
From embodiment 2, Radix Ginseng total saponins is taken from embodiment 3.
Experimental example 1 KWR compositions drug combination drug efficacy study
Test sample: blank group: 0.9% normal saline solution, self-control;
Model group: 0.9% normal saline solution, self-control;
Kurarinone group: Matrine Injection, Tianjin Biochemical Pharmaceutical Factory;
Fructus Schisandrae Chinensis group: Fructus Schisandrae Chinensis extrat injection, self-control;
Ginseng polysaccharide group: the ginseng polysaccharide, the made ginseng polysaccharide of embodiment 1 is taken from self-control;
The Radix Ginseng total saponins group: Radix Ginseng total saponins, the made Radix Ginseng total saponins of embodiment 2 is taken from self-control;
The different proportioning groups of KWR composition I: the different proportionings of KWR composition I injection (kurarinone+Fructus Schisandrae Chinensis extrat+ginseng polysaccharide), self-control (preparation method is referring to embodiment 4);
The different proportioning groups of KWR composition I I: the different proportionings of KWR composition I I injection (kurarinone+Fructus Schisandrae Chinensis extrat+Radix Ginseng total saponins), self-control (preparation method is referring to embodiment 5).
Laboratory animal: ICR mice, body weight 18～25g, male and female half and half.
Experimental technique: get 180 of mices, be divided into 18 groups at random, 10 every group, group sees the following form.Blank group and model group tail vein injection saline every day 20ml/kg Mus are heavy, every day 1 time, 10d continuously; The administration of administration group tail vein injection, every day 1 time, dosage sees the following form, continuously 10d.The blank group is tail vein injection 6h pneumoretroperitoneum injecting normal saline the last time.Model group and administration group tail vein injection 6h pneumoretroperitoneum injection with acetaminophen 300mg/kg Mus the last time are heavy, each group breaks end behind intraperitoneal injection of saline and acetaminophen 16h, get blood, liver, carry out the test of biochemical indicator Serum ALT (glutamate pyruvate transaminase) and hepatic tissue LPO (lipid peroxide), the results are shown in Table 1.
The influence of table 1KWR compositions Abensanil damage murine liver tissue ALT and LPO
Compare with the blank group,
◇ ◇P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01; Compare with the kurarinone group, #P＜0.05,
##P＜0.01; Compare with the Fructus Schisandrae Chinensis group,
△P＜0.05,
△ △P＜0.01; Organize comparison with the ginseng polysaccharide,
☆P＜0.05,
☆ ☆P＜0.01; Compare with the Radix Ginseng total saponins group,
﹠amp;P＜0.05,
﹠amp; ﹠amp;P＜0.01.
Conclusion: compare with the blank group, the active of model group ALT and LPO significantly raises, and significant difference (P＜0.01) illustrates that modeling is reliable.Compare with model group; active (P＜0.05 that obviously reduces of kurarinone group, Fructus Schisandrae Chinensis group, ginseng polysaccharide's group, Radix Ginseng total saponins group and KWR composition I and each proportioning group ALT of KWR composition I I and LPO; P＜0.01), illustrates that the hepatic injury of the equal Abensanil induced mice of each medicine has protective effect.Wherein each proportioning group better efficacy (P＜0.01) of KWR composition I and KWR composition I I all is better than single kurarinone, Fructus Schisandrae Chinensis, ginseng polysaccharide or Radix Ginseng total saponins used, and illustrates that kurarinone, Fructus Schisandrae Chinensis and Radix Ginseng three medicines share, and have synergistic function.In KWR composition I and each proportioning group of KWR composition I I, all remarkable with kurarinone+Fructus Schisandrae Chinensis+Radix Ginseng (400mg+3g+4g) group curative effect.
Experimental example 2 KWR compositionss are to carbon tetrachloride (CCl
4) cause the protective effect of chmice acute hepatic injury
Test sample: blank group: 0.9% normal saline solution, self-control;
Model group: 0.9% normal saline solution, self-control;
Kurarinone group: Matrine Injection, Tianjin Biochemical Pharmaceutical Factory, 2ml:0.2g;
The basic, normal, high dosage group of KWR composition I: KWR composition I injection, self-control (preparation method is referring to embodiment 4);
The basic, normal, high dosage group of KWR composition I I: KWR composition I I injection, self-control (preparation method is referring to embodiment 5).
Laboratory animal: ICR mice, body weight 22～24g, male and female half and half.
Experimental technique: get 90 of mices, be divided into 9 groups at random, be respectively blank group, model group, kurarinone group, the basic, normal, high dosage group of KWR composition I and the basic, normal, high dosage group of KWR composition I I, 10 every group.Blank group and model group tail vein injection saline every day 20ml/kg Mus are heavy, every day 1 time, 7d continuously; The administration of administration group tail vein injection, every day 1 time, dosage sees the following form, continuously 7d.The blank group is tail vein injection 2h pneumoretroperitoneum injection Oleum Arachidis hypogaeae semen 10ml/kg the last time, the equal lumbar injection 0.12%CCl of all the other each treated animals
4Peanut oil solution 10ml/kg, overnight fasting.Sacrificed by decapitation animal behind the 16h, the value of getting serologic test ALT, AST.After broken end is got blood, cut open the belly immediately and take out liver, spleen, inhale the liquid of dehematizing, cut off fat, mesentery, the weight of the liver of accurately weighing, spleen.The results are shown in Table 2.
Table 2 KWR compositions is to CCl
4Due to the influence of acute liver damage Mouse Liver, spleen index and Serum ALT, AST content
Compare with the blank group
◇P＜0.05,
◇ ◇P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01; Compare with the kurarinone group,
#P＜0.05,
##P＜0.01
Conclusion: CCl
4Model group Mouse Liver index, the normal control group mice numerical value of spleen index increase (P＜0.05), CCl
4Model group mice serum ALT, the normal control group mice numerical value of AST value increase (P＜0.01), and injected in mice CCl is described
4Hepar damnification behind the peanut oil solution, the modeling success, model stability is reliable.Compare with model group, KWR composition I and the middle and high dosage group of KWR composition I I Mouse Liver index, spleen index reduce (P＜0.05), liver, splenomegaly alleviate, each dosage group Serum ALT of KWR composition I and KWR composition I I, AST value obviously reduce (P＜0.05 or P＜0.01), illustrate that the present composition is to CCl
4Due to acute liver damage protective effect is arranged.Wherein each dosage group curative effect of compositions all is better than singly using kurarinone, illustrates that kurarinone, Fructus Schisandrae Chinensis and Radix Ginseng three medicines share, and have synergistic function.
Experimental example 3 KWR group contains the anti-dhbv dna effect of thing
Test sample: blank group: 0.9% normal saline solution, self-control;
Kurarinone group: Matrine Injection, Tianjin Biochemical Pharmaceutical Factory, 2ml:0.2g;
Positive controls: injection acyclovir, Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Shiyao Group;
The basic, normal, high dosage group of KWR composition I: KWR composition I injection, self-control (preparation method is referring to embodiment 4);
The basic, normal, high dosage group of KWR composition I I: KWR composition I I injection, self-control (preparation method is referring to embodiment 5).
Laboratory animal: commercially available 1 age in days Beijing duck;
DHBV (hepatitis B virus) positive serum, microbiology teaching and research room of Medical Center of Fudan University.
Experimental technique:
4.1 the animal model Beijing duck is got blood through sufficient intravenous injection 0.2mlDHBV positive serum behind the 7d, separation of serum, and-20 ℃ of preservations are to be checked.
4.2 Drug therapy filters out 54 of the positive ducks that infect successfully, is divided into 9 groups at random, is respectively blank group, kurarinone group, positive controls, the basic, normal, high dosage group of KWR composition I and the basic, normal, high dosage group of KWR composition I I, 6 every group.The blank group is irritated stomach normal saline 20ml/kg every day, every day 2 times, 14d continuously; Administration group gastric infusion, every day 2 times, dosage sees the following form, continuously 14d.Positive drug is pressed 100mg/kg with ACV and is irritated stomach, 2 times/d, 2 weeks of administration as the treatment matched group.Be respectively applied for (1d), the 7th day (T of medication before the medicine
7), the 14th day (T of medication
14) and drug withdrawal after the 7th day (P
7).Get blood from duck lower limb shin vein, separation of serum ,-20 ℃ of preservations are to be checked.Adopt the DHBV-DNADotBlot method, with hybridization spot absorbance (A) as specimen DHBV-DNA level value.The results are shown in Table 3.
Table 3 KWR compositions is to the inhibitory action of DHBV-DNA
Annotate: compare with the blank group
◇P＜0.05,
◇ ◇P＜0.01; With compare before the administration
@P＜0.05,
@@P＜0.01.
Conclusion: positive control (acyclovir) group after administration the 7th day and the 14th day, with before the administration and with the blank group relatively, difference has significance (P＜0.01), but significantly rising again after the drug withdrawal does not have significance (P＞0.05) with comparing difference before the administration.Various dose KWR composition I and KWR composition I I all have inhibitory action to DHBV, and do not have knock-on after the drug withdrawal, and wherein middle and high dosage group inhibitory action is more obvious.The all excellent son of each administration group curative effect of KWR composition I and KWR composition I I is single uses kurarinone, illustrates that kurarinone, Fructus Schisandrae Chinensis and Radix Ginseng three medicines share, and have synergistic function.
The Hepar Mus fibrosis effect of the experimental example 4 KWR compositions Chinese People's Anti-Japanese Military and Political College
Test sample: blank group: 0.9% normal saline solution, self-control;
Model group: 0.9% normal saline solution, self-control;
Kurarinone group: Matrine Injection, Tianjin Biochemical Pharmaceutical Factory, 2ml:0.2g;
The basic, normal, high dosage group of KWR composition I: KWR composition I injection, self-control (preparation method is referring to embodiment 4);
The basic, normal, high dosage group of KWR composition I I: KWR composition I I injection, self-control (preparation method is referring to embodiment 5).
Laboratory animal: the Wistar rat, body weight 180～230g, male.
Experimental technique: get 10 of healthy rats, subcutaneous injection Oleum Arachidis hypogaeae semen 3ml/kg, every day 1 time, totally 10 weeks, group in contrast.The Liver Fibrosis Model group is used 40%CCl
4Peanut oil solution is pressed the 3ml/kg subcutaneous injection, 2 times weekly, in totally 8 weeks, induces Liver Fibrosis Model.Get 80 of Liver Fibrosis Model rats, be divided into 8 groups at random, be respectively model group, kurarinone group, the basic, normal, high dosage group of KWR composition I and the basic, normal, high dosage group of KWR composition I I, 10 every group.Except that matched group, all the other each groups continue with 40%CCl
4Peanut oil solution 3ml/kg subcutaneous injection, every day 1 time.The basic, normal, high dosage group of kurarinone group, the basic, normal, high dosage group of KWR composition I and KWR composition I I is the gastric infusion relative medicine simultaneously, and dosage sees the following form.Continue 2 weeks of administration.Slaughter rat after 10 weeks, blood 2ml gets in the sterile working, separation of serum, and-20 ℃ of preservations detect hepatic fibrosis index with radioimmunology: hyaluronic acid (HA) and laminin (LN); Detect glutamate pyruvate transaminase (ALT) and glutamic oxaloacetic transaminase, GOT (AST) with biochemical process, adopt automatic clinical chemistry analyzer to detect.The results are shown in Table 4.
Table 4 KWR compositions is to CCl
4Due to the influence of serological index of hepatic fibrosis rats
Compare with the blank group
◇ ◇ ◇P＜0.001; Compare with model group,
*P＜0.05,
*P＜0.01: compare with the kurarinone group,
#P＜0.05.
Conclusion: compare with the blank group, model group rat blood serum ALT, AST, HA, LN content have significant difference, illustrate that model stability is reliable.Kurarinone, KWR composition I and KWR composition I I treatment heptic fibrosis rat blood serum ALT and AST all are lower than model group, difference has significance (P＜0.05 or P＜0.01), and prompting kurarinone, KWR composition I and KWR composition I I have the effect of falling enzyme and liver function protecting; Kurarinone, KWR composition I and KWR composition I I treatment back serum HA and LN level all significantly are lower than model group, difference has significance (P＜0.05 or P＜0.01), prompting kurarinone, KWR composition I and KWR composition I I all have the hepatic fibrosis of improvement serological index, have the effect of anti-hepatic fibrosis.Wherein, KWR composition I and KWR composition I I group curative effect are better than the kurarinone group, and prompting kurarinone, Fructus Schisandrae Chinensis and Radix Ginseng three medicines share, and synergistic function is arranged.
Experimental example 5 injected in mice administration acute toxicity testings
(1) experimental technique
Test sample: KWR composite injection I, dosage form: liquid drugs injection, specification: 5ml derives from embodiment 4;
KWR composite injection II, dosage form: liquid drugs injection, specification: 5ml derives from embodiment 5.
Animal subject: mice, each 5 of every group of male and female, male body weight 25～28g, female body weight 21～24g.
Route of administration: intravenous injection, lumbar injection.
Observation item: death toll, general state, body weight, cut open inspection, half lethal dose.
(2) experimental result
Require to carry out prerun according to acute toxicity testing, lumbar injection and intravenous injection two route of administration all can't be measured the median lethal dose(LD 50) of medicine, also do not see tangible toxic reaction, so carry out maximum dosage-feeding experiment in a day.Dosage: the tail vein is injected KWR composite injection I, each 0.1ml/10g of KWR composite injection II respectively, and the abdominal cavity is injected KWR composite injection I, each 0.1ml/10g of KWR composite injection II, 2 times on the one respectively.
Death toll: do not occur dead.
General state: no abnormality seen changes.
Body weight: in administration preceding 1 day, administration day, measured in 1,3,7,14 day after the administration; No abnormality seen changes.
Cut open inspection: the heart, liver, lung, kidney etc. organize no abnormality seen to change.
(3) conclusion
Occur death in this experiment, infer that KWR composite injection I, II are 0.2ml/10g to the maximum tolerated dose of male and female mouse vein and intraperitoneal injection, are equivalent to 100 times of maximum consumption 10ml of the 50kg body weight day for human beings.Show this product low toxicity, safe.
Experimental example 6 KWR composite injection stability experiments
Test sample: KWR composite injection I, dosage form: liquid drugs injection, specification: 5ml derives from embodiment 4;
KWR composite injection II, dosage form: liquid drugs injection, specification: 5ml derives from embodiment 5.
Investigation project: character, pH value, clarity
Long-time stability experimental technique and result: each compositions of this product is put under the condition of 25 ℃ ± 2 ℃ of temperature, relative humidity 60% ± 10% and placed 6 months, 12 months, every index has no significant change, and experimental result shows that the long-term placement of each composite injection of this product is basicly stable.
4, the specific embodiment
The specific embodiment of form is described in further detail foregoing of the present invention by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following embodiment.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.The adjuvant of each dosage form can be replaced with acceptable accessories in following examples, perhaps reduces, increases.Used Fructus Schisandrae Chinensis extrat is taken from embodiment 1 among the embodiment 4～17, and the ginseng polysaccharide takes from embodiment 2, and Radix Ginseng total saponins is taken from embodiment 3.
The preparation of embodiment 1 Fructus Schisandrae Chinensis extrat
Get schisandra chinensis medicinal material, be ground into coarse powder, decoct with water 2 times, per 2 hours, filter, filtrate is concentrated into the concentrated solution of relative density 1.10～1.15, add ethanol and make and contain alcohol amount and reach 60%, cold preservation was placed 24 hours, filtered, filtrate recycling ethanol also is concentrated into the concentrated solution of relative density 1.10～1.15, adds ethanol again and makes and contain the alcohol amount and reach 80%, and cold preservation was placed 24 hours, filter, filtrate recycling ethanol also is concentrated into the thick paste of relative density 1.30～1.35, vacuum drying, promptly.
By the Fructus Schisandrae Chinensis extrat that this technology makes, yield is 2～4%.Schisandrin content is not less than 10% in the extract; Ether-soluble extractives content is not less than 30%.
The discriminating of Fructus Schisandrae Chinensis extrat
Get this product powder 1g, add chloroform 20ml, reflux 20 minutes filters, and filtrate evaporate to dryness, residue add chloroform 1ml makes dissolving, as need testing solution.Other gets Fructus Schisandrae Chinensis control medicinal material 1g, shines medical material solution in pairs with legal system.Get the deoxyschizandrin reference substance again, add chloroform and make the solution that every 1ml contains 1mg, in contrast product solution.According to the thin layer chromatography test, draw each 2 μ l of above-mentioned three kinds of solution, put in same silica gel G F respectively
254On the lamellae, be developing solvent, launch, take out, dry, put under the ultra-violet lamp (254nm) and inspect with the upper solution of petroleum ether (30～60 ℃)-Ethyl formate-formic acid (15: 5: 1).In the test sample chromatograph, with control medicinal material and the corresponding position of reference substance chromatograph on, show the speckle of same color.
The assay of Fructus Schisandrae Chinensis extrat
The assay of schisandrin
Measure according to high performance liquid chromatography (appendix VID).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Methanol-water (13: 7) is a mobile phase; The detection wavelength is 250nm.Number of theoretical plate calculates by the schisandrin peak should be not less than 2000.
Schisandrin reference substance 15mg is got in the preparation of reference substance solution, accurate claims surely, puts in the 50ml measuring bottle, with dissolve with methanol and be diluted to scale, shakes up, and promptly gets (every 1ml contains schisandrin 0.3mg).
The about 0.1g of this product powder is got in the preparation of need testing solution, and accurate the title decides, and puts in the 25ml measuring bottle, adds the about 20ml of methanol, and supersound process (power 250W, frequency 44kHz) 20 minutes is taken out, and adds methanol to scale, shakes up, and filters, promptly.
Accurate respectively reference substance solution and each the 10 μ l of test solution of drawing of algoscopy inject chromatograph of liquid, measure, promptly.
The assay of ether-soluble extractives
Measure according to volatility ether determination of extractives method (appendix X).
Get this product powder (cross No. four sieve) 4g, put in the phosphorus pentoxide desiccator dry 12 hours, put in the apparatus,Soxhlet's, it is an amount of to add diethyl ether, reflux 8 hours is got ether solution, puts in the evaporating dish that is dried to constant weight, place, fling to ether, residue was put in the phosphorus pentoxide desiccator dry 18 hours, accurate claim fixed, slowly be heated to 105 ℃, and be dried to constant weight in 105 ℃.It subtracts the weight that weight loss is volatility ether extractum.Calculate the ether extract content.
According to above-mentioned technology, make three batches of Fructus Schisandrae Chinensis extrat samples, its content and yield see the following form.By the result as can be seen, by the Fructus Schisandrae Chinensis extrat of this prepared, yield is 2～4%, and the content of schisandrin is not less than 10% in the extract, and ether-soluble extractives content is not less than 30%.
Embodiment 2 is that the Radix Ginseng extract of main effective ingredient is ginseng polysaccharide's preparation with polysaccharide
Get Radix Ginseng, chopping is used 75% ethanol, reflux, extract, 4 hours, filter, medicinal residues dry, and decoct with water five times, merge decoction liquor, add 0.3% active carbon, stirred 30 minutes, standing over night filters, filtrate is crossed resin column, collects effluent, and concentrating under reduced pressure adds ethanol and makes and contain the alcohol amount and reach 95%, cold preservation filters, and gets the precipitation washing with acetone, drain acetone, take out and be deposited in 60～80 ℃ of dryings, pulverize promptly.
Ginseng polysaccharide's identification experiment
(1) gets the about 0.2g of this product, after adding water 5ml dissolving, add 5 of alkaline cupric tartrate test solutions, heating promptly produces red precipitate, cooling, filter, get filtrate add 1 of hydrochloric acid make acid, heating in water bath 10 minutes, put cold, regulate pH value to neutral, add alkaline cupric tartrate test solution 0.5ml, heating in water bath promptly produces red copper oxidule precipitation.
(2) get the about 0.2g of this product, add water 2ml dissolving after, add 5% alpha-Naphthol alcoholic solution 0.5ml and shake up, slowly add sulphuric acid 3ml, two liquid level intersection displaing amaranth rings.
Ginseng polysaccharide's assay
The preparation precision of reference substance solution takes by weighing 60 ℃ of vacuum dryings to the about 100mg of the galacturonic acid of constant weight, puts in the 100ml measuring bottle, adds water to scale, shakes up.Precision is measured 10ml, puts in the 100ml measuring bottle, adds water to scale, shakes up, promptly.
The preparation precision of need testing solution takes by weighing this product 50mg, puts in the 100ml measuring bottle, is dissolved in water and is diluted to scale, shakes up, promptly.
The algoscopy precision is measured each 1ml of reference substance solution, need testing solution and water, the accurate respectively 0.25mol/L Borax sulfuric acid solution 6ml that adds, put in the water-bath heating 30 minutes, put cold, the accurate respectively again 0.125% carbazole ethanol solution 0.4ml that adds, put in the water-bath and heated 10 minutes, put and be chilled to room temperature,, measure trap at 530nm wavelength place according to spectrophotography (an appendix V of Chinese Pharmacopoeia version in 2000 B) experiment, calculate, promptly.
According to above-mentioned technology, make Radix Ginseng extract three batch samples, its content and yield see the following form.By the result as can be seen, by ginseng polysaccharide in ginseng polysaccharide's extract of this prepared, yield is 0.5～2%, and ginseng polysaccharide's content is not less than 50%.
Embodiment 3 is that the Radix Ginseng extract of main effective ingredient is the preparation of Radix Ginseng total saponins with total saponins
Radix Ginseng total saponins preparation technology:
Get the ginseng crude drug, be ground into particulate, the alcohol reflux secondary, each 3 hours, add 10 times of amounts of alcohol, merge extractive liquid,, cold preservation at every turn, filter, filtrate recycling ethanol also is concentrated into thick paste, adds water to an amount of (making every 1ml be equivalent to crude drug 1g), stirs evenly, cold preservation, filter, filtrate is added on the macroporous resin column of having handled well, and the water with 2V～3V column volume carries out eluting earlier, discard water lotion, 80% ethanol elution of 3 times of column volumes of reuse is collected eluent, reclaims ethanol and is evaporated to the thick paste of relative density 1.30～1.35, vacuum drying, promptly.
The discriminating of Radix Ginseng total saponins
Get this product 0.5g, add water 0.5ml and stir moistening, add water-saturated n-butanol 10ml, supersound process 30 minutes is drawn supernatant and is added 3 times of amount ammonia solutions, shakes up, and places layering, gets upper strata liquid evaporate to dryness, and residue adds methanol 1ml makes dissolving, as need testing solution.Other gets ginsenoside Re, Rg1 reference substance, adds methanol and makes the mixed solution that every 1ml contains 2mg, in contrast product solution.Draw above-mentioned two kinds of each 2ul of solution, put respectively on same silica gel g thin-layer plate, (15: 40: 22: 10) lower floor's solution of placing below 10 ℃ was developing solvent with chloroform-ethyl acetate-methanol-water, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, it is clear to be heated to speckle colour developing at 105 ℃, puts under the ultra-violet lamp (365nm) and inspects.In the test sample chromatograph, with reference substance chromatograph relevant position on show the fluorescence speckle of same color.
Determination of Total Saponin Content in Panax Ginseng
Reference substance solution preparation: get ginsenoside R
G1The about 10mg of reference substance through 60 ℃ of vacuum dryings 2 hours, accurately claims surely, puts in the 100ml measuring bottle, with anhydrous alcohol solution and be diluted to scale, shakes up, and makes every 1ml and contains R
G1The solution of reference substance 0.1mg, promptly.
The need testing solution preparation: precision takes by weighing this product 50mg, puts in the 50ml measuring bottle, adds dehydrated alcohol and is diluted to scale, shakes up, and precision is measured 2ml, puts in the 10ml measuring bottle, adds dehydrated alcohol and is diluted to scale, shakes up, promptly.
The algoscopy precision is measured need testing solution and each 1ml of reference substance solution, puts respectively in the 10ml tool plug test tube, and evaporate to dryness in water-bath is put cold, add 5% vanillin glacial acetic acid solution 0.2ml, add perchloric acid 0.8ml again, in 60 ℃ of insulations 15 minutes, be cooled to room temperature, add glacial acetic acid 5ml, shake up; Make blank simultaneously.According to spectrophotography (an appendix V of Chinese Pharmacopoeia version in 2000 B), measure trap at 560nm wavelength place, calculate, promptly.
Ginsenoside Re, ginsenoside Rg1's assay
Chromatographic condition and system suitability experiment are filler with the octadecylsilane chemically bonded silica; With acetonitrile-water (22: 78) is mobile phase; The detection wavelength is 203nm.Number of theoretical plate calculates by the ginsenoside Re peak should be not less than 2000.
The preparation precision of reference substance solution takes by weighing the ginsenoside Rg
1Reference substance, Re reference substance are an amount of, add methanol and make the mixed solution that every 1ml contains 0.2mg.
This product 0.2g is got in the preparation of need testing solution, and accurate the title decides, the accurate water-saturated n-butanol 30ml that adds, close plug, placement is spent the night, supersound process (power 250W, frequency 50kHz) 30 minutes, filter, discard filtrate just, precision is measured subsequent filtrate 15ml, puts evaporate to dryness in the evaporating dish, and residue adds dissolve with methanol and is transferred in the 5ml volumetric flask, add methanol and be diluted to scale, shake up, filter, get subsequent filtrate promptly.
Accurate respectively reference substance and each 20ul of need testing solution of drawing of algoscopy injects chromatograph of liquid, measures, promptly.The results are shown in following table.
According to above-mentioned technology, make Radix Ginseng total saponins three batch samples, its content and yield see the following form.By the result as can be seen, the Radix Ginseng total saponins extract yield that obtains by this prepared is 1～2%, and Radix Ginseng total saponins content is not less than 50%, ginsenoside Re, ginsenoside Rg
1Content is not less than 30%.
The preparation of embodiment 4 KWR composition I aqueous injection
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 10.0g
Water for injection adds to 5000ml
Prepare 1000 altogether
Preparation technology:
1) carries and handle the previous day such as pipeline that dosing uses and container etc., face with the fresh water for injection flushing of preceding reuse.
2) kurarinone and ginseng polysaccharide are added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat is added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.
3) merge above-mentioned solution, benefit adds to the full amount of water for injection.
4) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
5) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
6) through the microporous filter membrane fine straining of 0.45um.
7) clarity of inspection solution, the semi-finished product chemical examination.
8) with the solution sealing by fusing in glass ampule.
9) 100 ℃ of flowing steam sterilizations are 30 minutes.
10) while hot sample being put into 0.01% methylene blue solution hunts leak.
11) lamp inspection, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 5 KWR composition I I aqueous injection
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 20.0g
Water for injection adds to 5000ml
Prepare 1000 altogether
Preparation technology:
1) carries and handle the previous day such as pipeline that dosing uses and container etc., face with the fresh water for injection flushing of preceding reuse.
2) kurarinone is added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat and Radix Ginseng total saponins are added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.
3) merge above-mentioned solution, benefit adds to the full amount of water for injection.
4) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
5) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
6) through the microporous filter membrane fine straining of 0.45um.
7) clarity of inspection solution, the semi-finished product chemical examination.
8) with the solution sealing by fusing in glass ampule.
9) 100 ℃ of flowing steam sterilizations are 30 minutes.
10) while hot sample being put into 0.01% methylene blue solution hunts leak.
11) lamp inspection, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 6 KWR composition I injectable powder
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 10.0g
Mannitol 400.0g
Sterile water for injection adds to 3000ml
Prepare 1000 altogether
Preparation technology:
1) vessel of at first dosing being used and antibiotic glass bottle, plug etc. carry out aseptic process.
2) take by weighing raw material and adjuvant according to recipe quantity.
3) kurarinone and ginseng polysaccharide are added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat is added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.Merge above-mentioned solution, add sterile water for injection to full dose.
4) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
5) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
6) through the microporous filter membrane fine straining of 0.22um.
7) clarity of inspection solution, the semi-finished product chemical examination.
8) be sub-packed in the antibiotic glass bottle half tamponade.Sample is put into the freeze dryer lyophilization.Pre-freeze-45 ℃ 5 hours, low-temperature vacuum drying-45 ℃～0 ℃ 20 hours was warming up to 25 ℃ of vacuum dryings 3 hours then.
9) lyophilizing finishes, and lid is rolled in tamponade.
10) finished product is examined entirely, the packing warehouse-in.
Implement the preparation of 7 KWR composition I I injectable powder
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 20.0g
Mannitol 400.0g
Sterile water for injection adds to 3000ml
Prepare 1000 altogether
Preparation technology:
1) vessel of at first dosing being used and antibiotic glass bottle, plug etc. carry out aseptic process.
2) take by weighing raw material and adjuvant according to recipe quantity.
3) kurarinone is added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat and Radix Ginseng total saponins are added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.Merge above-mentioned solution, add sterile water for injection to full dose.
4) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
5) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
6) through the microporous filter membrane fine straining of 0.22um.
7) clarity of inspection solution, the semi-finished product chemical examination.
8) be sub-packed in the antibiotic glass bottle half tamponade.Sample is put into the freeze dryer lyophilization.Pre-freeze-45 ℃ 5 hours, low-temperature vacuum drying-45 ℃～0 ℃ 20 hours was warming up to 25 ℃ of vacuum dryings 3 hours then.
9) lyophilizing finishes, and lid is rolled in tamponade.
10) finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 8 KWR composition I sodium chloride transfusion
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 10.0g
Sodium chloride 900g
Water for injection adds to 100000ml
Prepare 1000 bottles altogether
Preparation technology:
1) handles the previous day such as pipeline that dosing uses and container etc., face with the fresh water for injection flushing of preceding reuse.
2) kurarinone and ginseng polysaccharide are added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat is added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.With sodium chloride with an amount of water for injection dissolving fully, merge above-mentioned solution, benefit adds to the full amount of water for injection.
3) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
4) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
5) through the microporous filter membrane fine straining of 0.45um.
6) clarity of inspection solution, the semi-finished product chemical examination.
7) fill is in the infusion bottle of 100ml.
8) 115 ℃ of pressure sterilizings are 30 minutes.
9) lamp inspection, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 9 KWR composition I I sodium chloride transfusion
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 20.0g
Sodium chloride 900g
Water for injection adds to 100000ml
Prepare 1000 bottles altogether
Preparation technology:
1) handles the previous day such as pipeline that dosing uses and container etc., face with the fresh water for injection flushing of preceding reuse.
2) kurarinone is added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat and Radix Ginseng total saponins are added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.With sodium chloride with an amount of water for injection dissolving fully, merge above-mentioned solution, benefit adds to the full amount of water for injection.
3) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
4) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
5) through the microporous filter membrane fine straining of 0.45um.
6) clarity of inspection solution, the semi-finished product chemical examination.
7) fill is in the infusion bottle of 100ml.
8) 115 ℃ of pressure sterilizings are 30 minutes.
9) lamp inspection, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 10 KWR composition I glucose infusion liquids
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 10.0g
Glucose 5000g
Water for injection adds to 100000ml
Prepare 1000 bottles altogether
Preparation technology:
1) carries and handle the previous day such as pipeline that dosing uses and container etc., face with the fresh water for injection flushing of preceding reuse.
2) kurarinone and ginseng polysaccharide are added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat is added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.Merge above-mentioned solution, benefit adds to the full amount of water for injection.Glucose is complete with the water for injection dissolving of dosing amount 40%, heated and boiled 15 minutes.
3) merge above-mentioned solution, benefit adds to the full amount of water for injection.
4) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
5) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
6) through the microporous filter membrane fine straining of 0.45um.
7) clarity of inspection solution, the semi-finished product chemical examination.
8) fill is in the infusion bottle of 100ml.
9) 115 ℃ of pressure sterilizings are 30 minutes.
10) lamp inspection, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 11 KWR composition I I glucose infusion liquids
Prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 20.0g
Glucose 5000g
Water for injection adds to 100000ml
Prepare 1000 bottles altogether
Preparation technology:
1) carries and handle the previous day such as pipeline that dosing uses and container etc., face with the fresh water for injection flushing of preceding reuse.
2) kurarinone is added in the water for injection of dosing amount 30% the heated and stirred dissolving fully.Fructus Schisandrae Chinensis extrat and Radix Ginseng total saponins are added a small amount of water for injection, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.Merge above-mentioned solution, benefit adds to the full amount of water for injection.Glucose is complete with the water for injection dissolving of dosing amount 40%, heated and boiled 15 minutes.
3) merge above-mentioned solution, benefit adds to the full amount of water for injection.
4) needle-use activated carbon of adding dosing amount 0.1%, heated and stirred 15 minutes.
5) through sand filtration rod filtering decarbonization.Measure the also pH value of regulator solution.
6) through the microporous filter membrane fine straining of 0.45um.
7) clarity of inspection solution, the semi-finished product chemical examination.
8) fill is in the infusion bottle of 100ml.
9) 115 ℃ of pressure sterilizings are 30 minutes.
10) lamp inspection, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 12 KWR composition tablets
KWR composition I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Starch 40.0g
Microcrystalline Cellulose 40.0g
The 2%HPMC aqueous solution is an amount of
Magnesium stearate 5.0g
Carboxymethylstach sodium 10.0g
Prepare 1000 altogether
KWR composition I I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Starch 40.0g
Microcrystalline Cellulose 40.0g
The 2%HPMC aqueous solution is an amount of
Magnesium stearate 5.0g
Carboxymethylstach sodium 10.0g
Prepare 1000 altogether
Preparation technology:
1) it is standby kurarinone, ginseng polysaccharide's (or Radix Ginseng total saponins) and Fructus Schisandrae Chinensis extrat pulverize separately to be crossed 100 mesh sieves.
2) take by weighing raw material and adjuvant according to recipe quantity.
3) hypromellose 2% the aqueous solution made soluble in water is standby.
4) with ginseng polysaccharide's (or Radix Ginseng total saponins), Fructus Schisandrae Chinensis extrat, kurarinone, starch, microcrystalline Cellulose mix homogeneously, adding 2%HPMC aqueous solution is an amount of, stirs, and makes suitable soft material.
5) cross 20 mesh sieve system granules.
6) granule is dried under 60 ℃ condition.
7) dry good granule adds magnesium stearate and carboxymethylstach sodium, crosses 18 mesh sieve granulate, mix homogeneously.
8) sampling, the semi-finished product chemical examination.
9) the sheet weight sheet of determining according to chemical examination.
10) finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 13 KWR composition capsules
KWR composition I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Starch 20.0g
Microcrystalline Cellulose 60.0g
The 2%HPMC aqueous solution is an amount of
Magnesium stearate 5.0g
Prepare 1000 altogether
KWR composition I I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Starch 20.0g
Microcrystalline Cellulose 60.0g
The 2%HPMC aqueous solution is an amount of
Magnesium stearate 5.0g
Prepare 1000 altogether
Preparation technology:
1) it is standby kurarinone, ginseng polysaccharide's (or Radix Ginseng total saponins) and Fructus Schisandrae Chinensis extrat pulverize separately to be crossed 100 mesh sieves.
2) take by weighing raw material and adjuvant according to recipe quantity.
3) hypromellose 2% the aqueous solution made soluble in water is standby.
4) with ginseng polysaccharide's (or Radix Ginseng total saponins), Fructus Schisandrae Chinensis extrat, kurarinone, starch, microcrystalline Cellulose mix homogeneously, adding 2%HPMC aqueous solution is an amount of, stirs, and makes suitable soft material.
5) cross 20 mesh sieve system granules.
6) granule is dried under 60 ℃ condition.
7) dry good granule adds magnesium stearate, crosses 18 mesh sieve granulate, mix homogeneously.
8) sampling, the semi-finished product chemical examination.
9) loading amount of determining according to chemical examination incapsulates.
10) finished product is examined entirely, the packing warehouse-in.
Implement the preparation of 14 KWR composition granules
KWR composition I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Icing Sugar 1000.0g
The 2%HPMC50% alcoholic solution is an amount of
Prepare 1000 bags altogether
KWR composition I I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Icing Sugar 1000.0g
The 2%HPMC50% alcoholic solution is an amount of
Prepare 1000 bags altogether
Preparation technology:
1) it is standby sucrose to be pulverized 100 mesh sieves.It is standby that kurarinone, ginseng polysaccharide's (or Radix Ginseng total saponins) and Fructus Schisandrae Chinensis extrat pulverize separately are crossed 100 mesh sieves.
2) take by weighing raw material and adjuvant according to recipe quantity.
3) the method mix homogeneously that kurarinone, ginseng polysaccharide's (or Radix Ginseng total saponins), Fructus Schisandrae Chinensis extrat and Icing Sugar are progressively increased with equivalent, adding 2%HPMC50% alcoholic solution is an amount of, stirs, and makes suitable soft material,
4) cross 20 mesh sieve system granules.
5) granule is dried under 60 ℃ condition.
6) dried granule is crossed 18 mesh sieve granulate.
7) sampling, the content of principal agent is determined loading amount in the semi-finished product chemical examination granule.
8) packing, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 15KWR composition dripping agent
KWR composition I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Polyethylene glycol 6000 1000g
KWR composition I I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Polyethylene glycol 6000 1000g
Preparation technology:
Pulverized behind 100 mesh sieves kurarinone, ginseng polysaccharide's (or Radix Ginseng total saponins) and Fructus Schisandrae Chinensis extrat standby.With polyethylene glycol 6000 heating and melting in water-bath, treat to add kurarinone, ginseng polysaccharide's (or Radix Ginseng total saponins) and Fructus Schisandrae Chinensis extrat after whole fusions, stirring and dissolving, 60 mesh sieves filter, and keep 60 ℃ to splash in the liquid paraffin that is chilled to below 10 ℃ and make ball.
The preparation of embodiment 16 KWR composition soft agent
KWR composition I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Soybean oil 300.0g
Soybean phospholipid 40.0g
Cera Flava 20.0g
Prepare 1000 altogether
KWR composition I I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Soybean oil 300.0g
Soybean phospholipid 40.0g
Cera Flava 20.0g
Prepare 1000 altogether
Preparation technology:
With the soybean oil of recipe quantity and soybean phospholipid, Cera Flava heating and melting, mixing is put coldly, adds ginseng polysaccharide's (or Radix Ginseng total saponins), Fructus Schisandrae Chinensis extrat, kurarinone and grinds well, and is pressed into soft capsule and gets final product.
The preparation of embodiment 17 KWR composition oral liquid agent
KWR composition I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Ginseng polysaccharide 48.0g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 10g
Sodium benzoate 15g
Stevioside 10g
Purified water adds to 10000ml
Prepare 1000 altogether
KWR composition I I prescription:
Kurarinone 400.0g
Fructus Schisandrae Chinensis extrat 90.3g (being equivalent to Fructus Schisandrae Chinensis 3g)
Radix Ginseng total saponins 48.4g (being equivalent to Radix Ginseng 4g)
Polyoxyethylene sorbitan monoleate 20.0g
Sodium benzoate 15g
Stevioside 20.0g
Purified water adds to 10000ml
Prepare 1000 altogether
Preparation technology:
1) with heated and stirred dissolving in the water of kurarinone and ginseng polysaccharide's (or Radix Ginseng total saponins) adding dosing amount 30% fully.Fructus Schisandrae Chinensis extrat is added low amounts of water, add the polyoxyethylene sorbitan monoleate heated and stirred dissolving of recipe quantity.Merge above-mentioned solution, add purified water to full dose.
2) sodium benzoate and stevioside is complete with the water dissolution of dosing amount 20%.
3) merge above-mentioned two solution, mend and add water to full dose.
4) filtering with microporous membrane of mistake 0.8um.
5) semi-finished product chemical examination.
6) fill.Finished product is examined entirely, the packing warehouse-in.
Claims (3)
1. pharmaceutical composition for the treatment of hepatitis is characterized in that said composition made by following bulk drugs: 400 parts of kurarinones, 60～120 parts of Fructus Schisandrae Chinensis extrats, 20～80 parts of ginseng polysaccharides; Perhaps be: 400 parts of kurarinones, 60～120 parts of Fructus Schisandrae Chinensis extrats, 20～80 parts of Radix Ginseng total saponinss, schisandrin content is not less than 5% in the described Fructus Schisandrae Chinensis extrat, and the ether extract content is not less than 15%; Ginseng polysaccharide's content is not less than 30%; Radix Ginseng total saponins content is not less than 30%, ginsenoside Re wherein and ginsenoside Rg
1Content is not less than 15%.
2. pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition and mixing acceptable accessories make clinically any or pharmaceutically acceptable dosage form.
3. pharmaceutical composition as claimed in claim 2 is characterized in that clinically or pharmaceutically acceptable dosage form is injection or oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005101045532A CN1970001B (en) | 2005-11-22 | 2005-11-22 | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005101045532A CN1970001B (en) | 2005-11-22 | 2005-11-22 | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1970001A CN1970001A (en) | 2007-05-30 |
| CN1970001B true CN1970001B (en) | 2011-07-20 |
Family
ID=38111149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005101045532A Expired - Fee Related CN1970001B (en) | 2005-11-22 | 2005-11-22 | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1970001B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075277A (en) * | 2016-06-13 | 2016-11-09 | 山东中医药大学 | A kind of preparation method of Oxymatrine-phospholipid Complex enteric-soluble controlled-release capsule |
| CN108685885B (en) * | 2017-07-11 | 2023-11-17 | 南华大学 | Pharmaceutical composition containing Schisandrin A and its use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1602917A (en) * | 2004-07-28 | 2005-04-06 | 贵阳云岩西创药物科技开发有限公司 | 'Shengmai' formulation and its preparation process |
| CN1650996A (en) * | 2003-12-06 | 2005-08-10 | 山东绿叶天然药物研究开发有限公司 | Medicinal composition, its preparation method and application |
| CN1686388A (en) * | 2005-04-11 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Kangai drip pill for treating tumour, hepatitis B and its preparation method |
-
2005
- 2005-11-22 CN CN2005101045532A patent/CN1970001B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650996A (en) * | 2003-12-06 | 2005-08-10 | 山东绿叶天然药物研究开发有限公司 | Medicinal composition, its preparation method and application |
| CN1602917A (en) * | 2004-07-28 | 2005-04-06 | 贵阳云岩西创药物科技开发有限公司 | 'Shengmai' formulation and its preparation process |
| CN1686388A (en) * | 2005-04-11 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Kangai drip pill for treating tumour, hepatitis B and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 张晶等.中药五味子化学成分和药理作用研究及临床应用.上海预防医学杂志9 4.1997,9(4),189-190. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1970001A (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101342229B (en) | Composition of Canton love-pea vine extract, preparation method and pharmaceutical use | |
| CN1899361B (en) | Zhenqi medicinal composition and its preparation | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN1985864B (en) | Medicine composition prepared mainly from glycyrrhizic acid or its salt, ginseng and glossy ganoderma | |
| CN100584348C (en) | A kind of anti-hepatitis pharmaceutical composition | |
| CN1970001B (en) | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis | |
| CN100525809C (en) | Medicinal composition of milkvetch root, chinaroot greenbrier and Hong Jingtian and its making method | |
| CN100574768C (en) | A kind of anticancer pharmaceutical composition and its production and use | |
| CN1985873B (en) | Medicine composition of glycyrrhizic acid or its salt, ginseng and astragalus root | |
| CN1969937B (en) | Pharmaceutical composition for treating hepatitis | |
| CN1977887B (en) | Medicinal composition for treating hepatitis | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN1977889A (en) | Medicinal composition of astragalus, salvia miltrorrhiza and oxymatrine, and its preparing method | |
| CN1977886B (en) | Medicinal composition of oxymatrine, ganoderma lucidum and astragalus | |
| CN1961898B (en) | An antitumor compound pharmaceutical composition with barbed stullcap and preparation process thereof | |
| CN102349956B (en) | Compound extract for moisturizeing pathogenic dryness and relieving itching and preparation thereof | |
| CN101011543B (en) | A new antitumor drug composition | |
| CN1961895B (en) | A novel anticancer pharmaceutical composition and preparation method thereof | |
| CN1961894B (en) | A novel compound pharmaceutical composition, preparation method and use thereof | |
| CN1939417B (en) | Medicinal composition of douricine, tinosporae or its extract | |
| CN100482266C (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN101081240A (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN101073611B (en) | Medicinal composition for preventing tumor | |
| CN1969957B (en) | Pharmaceutical composition comprising flavescent sophora root, magnolia vine fruit and astragalus root | |
| CN1969922B (en) | Compound pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080530 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Dongchen street, Ji'nan high tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Dongchen street, Ji'nan high tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20131008 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131008 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Dongchen street, Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110720 Termination date: 20191122 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |